Japanese

Department of Immune Regulation

Our scope is the analysis of the human immune response against malaria, especially relate to malaria vaccine development.

Member of Immune Regulation

Members

  • Associate Professor Shusaku Mizukami
  • Research Fellow Sayuri Nakamae
  • Research Fellow Satoshi Miyagawa (Cellular Architecture Studies)
  • Assistant Mayumi Taniguchi
  • Assistant Akiko Noguchi
  • Graduate student Mariko Kamiya (immunogenetics)

Activities

The life cycle in human body of the protozoan parasite Plasmodium, responsible of malaria, is divided into two stages; erythrocyticand liver- stage. Even with argent appearance of drug resistant strain, there are many current antimalarial drugs available for the erythrocytic stage. On the other hand, for the liver-stage, there are few drugs available with undesirable side effects, thus vaccine and drug development are still an urgent issue for this stage.

Cellular immunity including cytotoxic T lymphocytes (CTL) is considered essential for protection against liver stage malaria. But many vaccine development aim to induce neutralizing antibody, the main effector of humoral immunity, and cellular immunity has not been considered enough.

Therefore, we focus on the liver stage malaria as the target for our cellular immunity based vaccine development. Our plan is to examine and optimize: a. vaccine antigen which lead the protection by cellular immunity, b. the targeted antigen delivery system c. the adjuvant and route of administration to enhance immune response.

First, our study will use mouse malaria model, and aim to apply our research finding for human malaria especially for P. falciparum. We hope our study will contribute to developing a better malarial vaccine candidate.

         Recent main research achievement
1. Phuong et al. Ann Clin Microbiol Antimicrobe 2019;18(1):10.
2. Manh et al. J Gen Viol 2018;99(9):1239-1247.
3. Tani et al. J Med Chem 2018;61(14):6399.
4. Inokuchi et al. Arch Viol 2018;163(9):2337-2347.
5. Mosaddeque et al. Antimicrob Agents Chemother 2018;62(5):e02424-17.

Return to Top of Shionogi Global Infectious Diseases Division»